NPC(SH:600713)2016-04-15 16:00Financial Performance - The audited net profit for 2015 was CNY 137,894,601.14, after offsetting previous losses of CNY 98,481,014.89 and allocating CNY 3,941,358.63 to statutory surplus reserves, leaving CNY 35,472,227.62 available for distribution to shareholders[4]. - The company reported a revenue of CNY 24,813,087,318.02 for 2015, representing a 12.40% increase compared to CNY 22,075,780,808.14 in 2014[21]. - The net profit attributable to shareholders of the listed company was CNY 156,724,461.80, reflecting a 21.60% increase from CNY 128,880,146.09 in the previous year[21]. - The net profit attributable to shareholders increased significantly by 154.43% from CNY 57,102,336.80 in 2014 to CNY 145,287,190.14 in 2015[21]. - The company reported a total revenue of CNY 24.81 billion for the year 2015, ranking sixth in the domestic pharmaceutical distribution industry[33]. - The company achieved a 153.13% increase in basic earnings per share after deducting non-recurring gains and losses, reaching CNY 0.162 in 2015[23]. - The company reported a total revenue of 222,175.94 million CNY for the year 2015, with a net profit of 1,429.65 million CNY, indicating a strong performance in the pharmaceutical distribution industry[94]. Dividend Distribution - The company plans to distribute a cash dividend of CNY 0.2 per 10 shares, totaling CNY 17,948,511.96, with CNY 17,523,715.66 carried forward for future distribution[4]. - The total distributable profit for shareholders in 2015 was ¥35,472,227.62, with a cash dividend of ¥0.2 per 10 shares, amounting to a total distribution of ¥17,948,511.96, resulting in a cash dividend payout ratio of 50.60%[110]. - The company plans to prioritize cash distribution to shareholders, with a commitment to maintain a cash dividend ratio of no less than 30% of the distributable profit in future years[110]. - The company plans to strengthen its cash dividend distribution, ensuring that the cash dividend ratio will not be less than 30% of the distributable profits for the year[116]. Operational Efficiency - The cash flow from operating activities showed a negative net amount of CNY -306.08 million in 2015[22]. - The weighted average return on equity decreased by 3.964 percentage points to 7.059% in 2015, compared to 11.023% in 2014[23]. - The company maintained a total expense ratio of 4.63%, a decrease of 0.66 percentage points compared to the previous year[54]. - The company is leveraging information technology to enhance supply chain efficiency and reduce logistics costs, aligning with industry trends[44]. - The company is enhancing its integrated supply chain system by leveraging big data for better service delivery across the pharmaceutical production and sales processes[50]. Market Position and Strategy - The company was ranked 235th in the China Top 500 Enterprises list for 2015, an improvement of 28 places from the previous year[33]. - The company is actively expanding into new markets, including Hubei, Yunnan, and Sichuan provinces, beyond its established regions[36]. - The company is focusing on transforming its retail operations from a product-centric model to a patient-centered service model[38]. - The company aims to maintain sales growth at least in line with the industry average, focusing on consolidating and expanding regional market share amidst ongoing drug bidding processes[98]. - The company is committed to building an integrated supply chain focused on healthcare consumption needs, aiming to become a trusted provider of health products and services in East China[97]. Risks and Compliance - The report includes a detailed description of potential risks faced by the company, which investors should review[6]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[6]. - The company has not violated any decision-making procedures in providing guarantees[6]. - The company has not reported any significant litigation or arbitration matters that could impact its financial position[121]. - The company has not faced any risks of suspension of listing during the reporting period[121]. Investments and Financing - The total investment amount for the year was CNY 394.63 million, reflecting a 56.40% increase compared to the previous year's investment of CNY 252.32 million[88]. - The company issued a total of RMB 20 billion in short-term financing bonds, with the first issuance in 2015 amounting to RMB 800 million at an interest rate of 4.15%[150][151]. - The company registered to issue a non-public debt financing tool not exceeding RMB 1 billion, which was approved by the shareholders' meeting[157]. - The company has diversified its financing channels, reducing traditional credit loan scales to below 50% of its total financing[143]. Corporate Governance - The company has appointed KPMG Huazhen LLP as its financial audit and internal control audit institution for the 2015 fiscal year, with an audit fee not exceeding RMB 3.3 million[119]. - The company’s board approved the annual related party transaction plan during the shareholder meeting held on May 8, 2015[128]. - The company has a structured management team with various vice presidents and independent directors, ensuring governance and oversight[191]. - The company maintains transparency in its executive compensation practices, aligning with shareholder interests[198]. Shareholder Information - The total number of ordinary shareholders reached 90,555 by the end of the reporting period, an increase from 85,690 previously[168][169]. - The actual controller of the company is the Nanjing Municipal Government State-owned Assets Supervision and Administration Commission[180]. - The company has disclosed changes in shareholding and management compensation, with total pre-tax remuneration for the chairman at 732,400 RMB[191]. - The company has no known related party relationships among the top ten shareholders[172].